Fusion Pharma hits record low after delay in cancer drug trials

Fusion Pharmaceuticals

09/06/2022 15:02

** Fusion Pharmaceuticals Inc's  FUSN.O  shares fall 6.8% to
a record low of $3.41 in thin early trading
    ** Drug developer pushes timeline for two trials of separate
cancer drug therapies citing a delay in starting operations at
the clinical sites  urn:newsml:reuters.com:*:nPn3BpJzya
    ** Expects data from an early-stage trial of its drug,
FPI-1434, in the first half of 2023 which was earlier expected
in the second half of 2022
    ** Co now expects to dose patients in a separate trial of
its other drug, FPI-1966, in H2 2022, earlier expected in Q2 
    ** Says enrollment in second study is being impacted by
staffing shortages at trial sites
    ** Including session fall, stock down ~25% YTD 

 (Reporting by Manas Mishra)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manaswrites15))